Palladio Biosciences is developing lixivaptan, a selective, oral, small molecule vasopressin V2 receptor antagonist for autosomal dominant polycystic kidney disease (ADPKD) with potential for a differentiated profile over the currently available treatment, tolvaptan.
Reason to Believe in Target
Precedented Human Activity
|Epidemiology~140,000 patients diagnosed in the United States||DiseaseAutosomal dominant polycystic kidney disease (ADPKD)|
Alex Martin, M.B.A – Chief Executive Officer
Lorenzo Pellegrini, Ph.D. – Founder & Chief Operating Officer
Neil H. Shusterman, M.D. – Chief Medical Officer